Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Cancer Conversations™: Experts Discuss and Debate Optimal Treatment of Relapsed/Refractory Multiple Myeloma
  • CME

Credits Available
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: March 31, 2021 Expiration: March 30, 2022
Start Activity
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
Bristol-Myers Squibb
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Oncopeptides
Shaji K. Kumar, MD
Program Director
Suzanne Lentzsch, MD, PhD
Saad Z. Usmani, MD, MBA, FACP

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the efficacy and safety evidence of novel combination therapeutic regimens for patients with R/R MM
  • Incorporate new and emerging therapies into treatment plans for patients with R/R MM based on available data and individual patient and disease characteristics
  • Manage toxicities associated with CAR T-cell therapy and BCMA-targeted therapies in patients with R/R MM
  • Evaluate ongoing major clinical trials investigating novel therapeutic approaches in R/R MM

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair,
Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, MedImmune, Oncopeptides, Takeda, and TeneoBio and consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Oncopeptides, and Takeda.

Faculty

Suzanne Lentzsch, MD, PhD

Director, Multiple Myeloma and Amyloidosis Program
Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Suzanne Lentzsch MD, PhD, has disclosed that she has received funds for research support from Karyopharm and Sanofi; has received consulting fees from AbbVie, Caelum, Celularity, GlaxoSmithKline, Karyopharm, Janssen, Sanofi, Sorrento, and Takeda; has received salary from Magenta; and has ownership interest in Caelum.
Saad Z. Usmani, MD, MBA, FACP

Clinical Professor of Medicine
Department of Hematologic Oncology & Blood Disorders
Division Chief
Plasma Cell Disorders Division
Levine Cancer Institute/Atrium Health
Charlotte, North Carolina

Saad Z. Usmani, MD, MBA, FACP, has disclosed that he has received funds for research support and consulting fees from Amgen, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Sanofi, Seagen, SkylineDx, Takeda, and TeneoBio and fees for non-CME/CE services from Amgen, Bristol-Myers Squibb/Celgene, Janssen, Sanofi, and Takeda.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Jerfiz Constanzo, PhD, MBA
Scientific Director
Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report
Gordon Kelley

Senior Clinical Editor

Gordon Kelley, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with relapsed/refractory multiple myeloma.

Goal

The goal of this activity is to educate hematologists, oncologists, and other healthcare professionals about the recent developments in the care of relapsed/refractory multiple myeloma and how to incorporate new data and new therapies into their patient treatment plans.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 31, 2021, through March 30, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Cancer Conversations™: Experts Discuss and Debate Optimal Treatment of Relapsed/Refractory Multiple Myeloma
  • CME

Loading...
Watch this on-demand webcast from a live webinar where experts discussed and debated the latest data for the management of patients with relapsed or refractory myeloma.
Shaji K. Kumar, MD
Program Director
Suzanne Lentzsch, MD, PhD
Saad Z. Usmani, MD, MBA, FACP
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: March 31, 2021 Expiration: March 30, 2022

Related Content

Downloadable slideset from Sagar Lonial, MD and Kathryn Maples, PharmD, BCOP on treatment options for patients with R/R myeloma, from Clinical Care Options (CCO).

Sagar Lonial, MD Kathryn Maples, PharmD, BCOP Released: May 4, 2021

Pharmacist’s perspective on improving management of CLL by discussing treatment options with patients, from Clinical Care Options (CCO)

Emily Bucholtz Headshot Emily Bucholtz, RPh Released: April 29, 2021

Steven Waguespack, MD, on hypothyroidism after immune checkpoint inhibitors, MIBG treatment, or mitotane, and the mechanism of hyperthyroidism in cancer survivors from Clinical Care Options (CCO)

Steven G. Waguespack, MD Released: April 26, 2021

Laurie Cohen, MD, on when and how to retest for GH deficiency, how soon to start GH replacement in cancer survivors from Clinical Care Options (CCO)

Laurie E. Cohen, MD Released: April 22, 2021
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
Bristol-Myers Squibb
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Oncopeptides

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue